BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Class Action Lawsuit Against Bolt Biotherapeutics: The Schall Law Firm has announced a class action lawsuit against Bolt Biotherapeutics for allegedly making false statements regarding the effectiveness of its cancer treatment drug, BDC-1001, and overstating its commercial prospects.
Investor Participation Encouraged: Investors who purchased Bolt's securities between February 5, 2021, and May 14, 2024, are urged to contact the firm before September 3, 2024, to discuss their rights and potential participation in the lawsuit.
Trade with 70% Backtested Accuracy
Analyst Views on BOLT
About BOLT
About the author
MAX Resource Corp. Completes Debt and Option Transactions with Bolt Metals
- Debt Settlement Transaction: MAX Resource Corp. has finalized a debt settlement with Bolt Metals, where Bolt issued 4,000,000 shares and 2,000,000 pre-funded warrants to MAX, which is expected to improve the company's financial position and support future project developments.
- Option Agreement Details: Under the amended option agreement, Bolt has the right to acquire 100% interest in the Florália High Purity Iron Property by issuing 26,800,000 Bolt shares to Max Iron, which is anticipated to enhance MAX's competitiveness in the iron ore market.
- Strategic Location Advantage: The Florália High Purity Iron Property is strategically located in Minas Gerais, Brazil, adjacent to major infrastructure and markets, which is expected to reduce transportation costs and improve logistics efficiency, thereby accelerating project development.
- Strong Exploration Potential: The initial oxide exploration target is estimated at 50 to 70 million tons with iron grades between 55% and 61%, indicating robust exploration potential that could attract investor interest.
Bolt Biotherapeutics Q1 Earnings Miss Expectations Significantly
- Earnings Miss: Bolt Biotherapeutics reported a Q1 GAAP EPS of -$4.31, missing expectations by $1.46, indicating significant challenges in profitability and investor confidence.
- Revenue Decline: The company's revenue plummeted to $0.03M, a staggering 97.5% year-over-year decrease, falling short of expectations by $1.47M, which may hinder future financing and growth prospects.
- Cash Position: As of March 31, 2026, Bolt Biotherapeutics held $23.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027, providing a short-term financial buffer amid operational challenges.
- Future Outlook: Despite the current financial setbacks, the company has sufficient cash reserves to sustain operations, necessitating a focus on product development and market strategy adjustments to improve performance and restore investor confidence.
Bolt Biotherapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Bolt Biotherapeutics reported a Q4 GAAP EPS of -$3.84, beating market expectations by $1.57, indicating improvements in cost control and operational efficiency.
- Revenue Growth: The company achieved revenue of $2.5 million in Q4, exceeding expectations by $1.64 million, suggesting increasing market acceptance of its products, which could lay the groundwork for future growth.
- Market Reaction: Although still in a loss position, the better-than-expected earnings report may boost investor confidence, potentially leading to a positive impact on stock prices and attracting more institutional investors.
- Future Outlook: The financial performance of Bolt Biotherapeutics demonstrates its potential in the biopharmaceutical sector, and if it can continue to improve its financial situation, it will help the company secure a more advantageous position in a competitive market.
Bolt Announces Q3 2025 Financial Results and Updates on Oncology Pipeline Advancements
Company Overview: Bolt Biotherapeutics, Inc. reported its Q3 2025 financial results, highlighting its focus on developing immunotherapies for cancer through its proprietary Boltbody ISAC platform, which includes two clinical-stage candidates, BDC-3042 and BDC-4182.
Clinical Trials Update: BDC-3042, targeting tumor-associated macrophages, has shown early signs of immune activation in a Phase 1 study, while BDC-4182 is being evaluated for gastric and gastroesophageal cancers, with initial data expected in Q3 2026.
Financial Performance: The company reported a narrowed net loss of $7.1 million for Q3 2025, a significant improvement from the previous year, attributed to reduced R&D and G&A costs following a corporate restructuring.
Stock Performance: Bolt's stock has fluctuated between $4.42 and $13 over the past year, closing at $4.69 recently, with a slight increase in overnight trading.
HC Wainwright & Co. Initiates Coverage on Bolt Biotherapeutics with a Buy Rating and Sets Price Target at $7
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community and Exclusivity: Joining Benzinga Pro connects traders with over 10,000 members and provides access to exclusive stories and insights from Benzinga reporters.
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Clinical Study Results: BDC-3042, a novel immunotherapy developed by Bolt Biotherapeutics, demonstrated a favorable safety profile and biological activity in a Phase 1 clinical trial, with no serious adverse events reported and signs of anti-tumor activity in patients with various cancers.
Future Development Plans: The company is seeking partnerships to accelerate the development of BDC-3042, which targets dectin-2 on tumor-associated macrophages, and aims to explore its potential in combination with other therapies for improved patient outcomes.
MAX Resource Corp. Completes Debt and Option Transactions with Bolt Metals
- Debt Settlement Transaction: MAX Resource Corp. has finalized a debt settlement with Bolt Metals, where Bolt issued 4,000,000 shares and 2,000,000 pre-funded warrants to MAX, which is expected to improve the company's financial position and support future project developments.
- Option Agreement Details: Under the amended option agreement, Bolt has the right to acquire 100% interest in the Florália High Purity Iron Property by issuing 26,800,000 Bolt shares to Max Iron, which is anticipated to enhance MAX's competitiveness in the iron ore market.
- Strategic Location Advantage: The Florália High Purity Iron Property is strategically located in Minas Gerais, Brazil, adjacent to major infrastructure and markets, which is expected to reduce transportation costs and improve logistics efficiency, thereby accelerating project development.
- Strong Exploration Potential: The initial oxide exploration target is estimated at 50 to 70 million tons with iron grades between 55% and 61%, indicating robust exploration potential that could attract investor interest.
Bolt Biotherapeutics Q1 Earnings Miss Expectations Significantly
- Earnings Miss: Bolt Biotherapeutics reported a Q1 GAAP EPS of -$4.31, missing expectations by $1.46, indicating significant challenges in profitability and investor confidence.
- Revenue Decline: The company's revenue plummeted to $0.03M, a staggering 97.5% year-over-year decrease, falling short of expectations by $1.47M, which may hinder future financing and growth prospects.
- Cash Position: As of March 31, 2026, Bolt Biotherapeutics held $23.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027, providing a short-term financial buffer amid operational challenges.
- Future Outlook: Despite the current financial setbacks, the company has sufficient cash reserves to sustain operations, necessitating a focus on product development and market strategy adjustments to improve performance and restore investor confidence.
Bolt Biotherapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Bolt Biotherapeutics reported a Q4 GAAP EPS of -$3.84, beating market expectations by $1.57, indicating improvements in cost control and operational efficiency.
- Revenue Growth: The company achieved revenue of $2.5 million in Q4, exceeding expectations by $1.64 million, suggesting increasing market acceptance of its products, which could lay the groundwork for future growth.
- Market Reaction: Although still in a loss position, the better-than-expected earnings report may boost investor confidence, potentially leading to a positive impact on stock prices and attracting more institutional investors.
- Future Outlook: The financial performance of Bolt Biotherapeutics demonstrates its potential in the biopharmaceutical sector, and if it can continue to improve its financial situation, it will help the company secure a more advantageous position in a competitive market.
Bolt Announces Q3 2025 Financial Results and Updates on Oncology Pipeline Advancements
Company Overview: Bolt Biotherapeutics, Inc. reported its Q3 2025 financial results, highlighting its focus on developing immunotherapies for cancer through its proprietary Boltbody ISAC platform, which includes two clinical-stage candidates, BDC-3042 and BDC-4182.
Clinical Trials Update: BDC-3042, targeting tumor-associated macrophages, has shown early signs of immune activation in a Phase 1 study, while BDC-4182 is being evaluated for gastric and gastroesophageal cancers, with initial data expected in Q3 2026.
Financial Performance: The company reported a narrowed net loss of $7.1 million for Q3 2025, a significant improvement from the previous year, attributed to reduced R&D and G&A costs following a corporate restructuring.
Stock Performance: Bolt's stock has fluctuated between $4.42 and $13 over the past year, closing at $4.69 recently, with a slight increase in overnight trading.
HC Wainwright & Co. Initiates Coverage on Bolt Biotherapeutics with a Buy Rating and Sets Price Target at $7
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community and Exclusivity: Joining Benzinga Pro connects traders with over 10,000 members and provides access to exclusive stories and insights from Benzinga reporters.
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Clinical Study Results: BDC-3042, a novel immunotherapy developed by Bolt Biotherapeutics, demonstrated a favorable safety profile and biological activity in a Phase 1 clinical trial, with no serious adverse events reported and signs of anti-tumor activity in patients with various cancers.
Future Development Plans: The company is seeking partnerships to accelerate the development of BDC-3042, which targets dectin-2 on tumor-associated macrophages, and aims to explore its potential in combination with other therapies for improved patient outcomes.
